SCHEMBL959953

SCHEMBL959953

Cc1cccc2[c]c[nH]c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
AHR P35869 1/20 0.36
KIF11 P52732 1/20 0.35
BRPF1 P55201 1/20 0.34
HTR2A P28223 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALDH1A1 P00352 2/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478128 0.74 AHR (0.42) AHRHTR2AGPR84CYP1A2CYP2A6
SCHEMBL1969683 0.74 CA12 (0.38) GPR84CA9DAO
SCHEMBL7288632 0.74 CA12 (0.38) AHRCA9
SCHEMBL9741961 0.74 DAO (0.32) DAO
SCHEMBL7288932 0.74 HPGD (0.35) CYP1A2MAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL3092127 0.74 ALDH1A1 (0.33) GPR84SMN1; SMN2ALDH1A1POLBTSHR
SCHEMBL7278500 0.74 IDO1 (0.32)
SCHEMBL1966772 0.74 CA1 (0.39) HTR2AMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL7279169 0.74 GABRA1 (0.39) MAPTALDH1A1GAATSHRDAO
SCHEMBL21053190 0.72 TRIM24 (0.46) TRIM24TRIM33AHRKIF11BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
CN-114249533-A Preparation method of graphene oxide glaze modified polished ceramic tile 广西蒙娜丽莎新材料有限公司 2022-03-29 CN claimed
CN-111747981-A Transition metal compound and preparation method and application thereof 万华化学集团股份有限公司 2020-10-09 CN claimed
EP-0958287-B2 SULFAMIDE-METALLOPROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-04-09 EP claimed
EP-1441719-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-04 EP claimed
WO-2003037327-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA-ROCHE AG (CH) 2003-05-08 WO claimed
EP-0958287-B1 SULFAMIDE-METALLOPROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2002-09-11 EP claimed
US-6143744-A Sulfamide-metalloprotease inhibitors SYNTEX (U.S.A.) INC. (US) 2000-11-07 US claimed
EP-0958287-A1 SULFAMIDE-METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 1999-11-24 EP claimed
WO-1998032748-A1 SULFAMIDE-METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 1998-07-30 WO claimed
US-5401738-A Angiotensin antagonist, hypotensive, aldosteronism, cardiac insufficiency MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) 1995-03-28 US claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US disclosed
CN-115785093-A Polycyclic quinazolinone derivative and preparation method and application thereof 齐齐哈尔医学院 2023-03-14 CN disclosed
CN-115260079-A Synthetic method of isatin and derivatives thereof 湖北可赛化工有限公司 2022-11-01 CN disclosed
CN-114195553-B Preparation method of fibrous nano-alumina modified ceramic glazed tile 广西蒙娜丽莎新材料有限公司 2022-09-30 CN disclosed
EP-0114603-A1 Indole derivatives MERCK PATENT GmbH (DE) 1984-08-01 EP disclosed
EP-0105397-A1 Sulphuric indole derivatives MERCK PATENT GmbH (DE) 1984-04-18 EP disclosed
EP-0007399-B1 INDOLYLALKYL AMINES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR MANUFACTURE MERCK PATENT GmbH (DE) 1982-01-20 EP disclosed
US-4251538-A Indolealkylamines and processes for their preparation MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1981-02-17 US disclosed
EP-0007399-A1 Indolylalkyl amines, pharmaceutical preparations containing them and process for their manufacture MERCK PATENT GmbH (DE) 1980-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 TRIM24 2499/4885TRIM33 4445/4885AHR 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.